Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Sponsor
Regeneron Pharmaceuticals (Industry)
Overall Status
Available
CT.gov ID
NCT05164250
Collaborator
(none)
Study Details
Study Description
Brief Summary
Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Regeneron Pharmaceuticals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT05164250
Other Study ID Numbers:
- R5458-MM
First Posted:
Dec 20, 2021
Last Update Posted:
Dec 20, 2021
Last Verified:
Dec 1, 2021
Keywords provided by Regeneron Pharmaceuticals
Additional relevant MeSH terms: